on NEOVACS (EPA:ALNEV)
Néovacs collaborates with the CNRS to develop mRNA lipid formulations
Néovacs, a biopharmaceutical company specializing in inflammatory and autoimmune diseases, has just signed a research partnership with the CNRS. This collaboration aims to develop new lipid formulations for the delivery of messenger RNA (mRNA).
The partnership brings together Néovacs and the team of Dr Nathalie Mignet from the CNRS. The UTCBS laboratory, headed by Dr Mignet, has recognized expertise in lipid vesicles intended for gene transfer.
As part of this collaboration, an engineer recently hired by Néovacs will carry out research aimed at optimizing these lipid formulations. The project will be financed by Néovacs to the tune of 100,000 euros, in exchange for an exclusive and worldwide exploitation right over the lipids developed.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NEOVACS news